Key result
Oral semaglutide shows no quantitative cardiovascular outcome results in the available data.
Why the study?
Does oral semaglutide improve cardiovascular outcomes compared to sitagliptin in a real-world primary prevention population?
Cohort
Does oral semaglutide improve cardiovascular outcomes compared to sitagliptin in a real-world primary prevention population?
Answers are grounded in this paper and cite their sources.
Observational cohort study examines cardiovascular outcomes in a primary prevention population taking oral semaglutide, highlighting real-world heart health effects.
Kevin Cowart: Research contract from Sanofi Winthrop Industrie, Abbott Diabetes Care, and the University of South Florida. Nicholas W. Carris: Paid advisor for Eli Lilly and Company as an independent contractor. Research contract with Sanofi Winthrop Industrie, with funds received and managed by the University of South Florida. All other authors reported nothing to disclose. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70412. Research data are not available as the analysis is conducted within the TriNetX analytics platform, without data export. Table S1. Query criteria for oral semaglutide cohort. Table S2. Query criteria for sitagliptin cohort. Table S3. Outcome definitions. Table S4. Incidence rates of cardiovascular outcomes per 1000 person-years. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Cowart et al. (2025) conducted a cohort in Primary prevention of cardiovascular outcomes. Oral semaglutide vs. Sitagliptin was evaluated on Cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: